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Abstract
Background/aims: In multi-site clinical trials, where trial data and conduct are scrutinised centrally with pre-specified
triggers for visits to sites, targeted monitoring may be an efficient way to prioritise on-site monitoring. This approach is
widely used in academic trials, but has never been formally evaluated.
Methods: TEMPER assessed the ability of targeted monitoring, as used in three ongoing phase III randomised multi-site
oncology trials, to distinguish sites at which higher and lower rates of protocol and/or Good Clinical Practice violations
would be found during site visits. Using a prospective, matched-pair design, sites that had been prioritised for visits after
having activated ‘triggers’ were matched with a control (‘untriggered’) site, which would not usually have been visited at
that time. The paired sites were visited within 4 weeks of each other, and visit findings are recorded and categorised
according to the seriousness of the deviation. The primary outcome measure was the proportion of sites with 1
‘Major’ or ‘Critical’ finding not previously identified centrally. The study was powered to detect an absolute difference of
30% between triggered and untriggered visits. A sensitivity analysis, recommended by the study’s blinded endpoint
review committee, excluded findings related to re-consent. Additional analyses assessed the prognostic value of individ-
ual triggers and data from pre-visit questionnaires completed by site and trials unit staff.
Results: In total, 42 matched pairs of visits took place between 2013 and 2016. In the primary analysis, 88.1% of trig-
gered visits had 1 new Major/Critical finding, compared to 81.0% of untriggered visits, an absolute difference of 7.1%
(95% confidence interval 28.3%, + 22.5%; p = 0.365). When re-consent findings were excluded, these figures reduced
to 85.7% versus 59.5%, (difference = 26.2%, 95% confidence interval 8.0%, 44.4%; p = 0.007). Individual triggers had
modest prognostic value but knowledge of the trial-related activities carried out by site staff may be useful.
Conclusion: Triggered monitoring approaches, as used in these trials, were not sufficiently discriminatory. The rate of
Major and Critical findings was higher than anticipated, but the majority related to consent and re-consent with no indi-
cation of systemic problems that would impact trial-wide safety issues or integrity of the results in any of the three trials.
Sensitivity analyses suggest triggered monitoring may be of potential use, but needs improvement and investigation of fur-
ther central monitoring triggers is warranted. TEMPER highlights the need to question and evaluate methods in trial con-
duct, and should inform further developments in this area.
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Introduction
Clinical trial monitoring is defined by the International
Conference on Harmonisation (ICH) as ‘The act of
overseeing the progress of a clinical trial, and ensuring
that it is conducted, recorded and reported in accor-
dance with the protocol, Standard Operating
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Procedures, Good Clinical Practice (GCP), and the
applicable regulatory requirements’, and aims to pro-
tect the rights and well-being of trial participants, while
ensuring protocol compliance and data integrity.1
Monitoring often relies on-site visits, an approach
recommended in ICH GCP guidance: ‘In general there
is a need for on-site monitoring .’ (section 5.18.3).1
Through that guidance, and following high-profile data
fraud cases,2 on-site monitoring has become a standard
means of ensuring GCP compliance since the 1990s, at
least in industry-sponsored trials. Visit activities com-
monly include intensive document review, in particular,
source data verification (SDV): the process of checking
case report form data against source notes. While this
may be done in a sample of patients, or on selected data
items on all patients, many trials’ site visits aim to check
100% of trial data.3 Intensive on-site monitoring has
been highlighted as inefficient and associated with sig-
nificant costs4–9 which are passed down to patients and
healthcare systems as drug development expenses.2,4
A growing body of evidence shows that 100% SDV
is of limited value.10–13 Trialists14,15 and regulators16–18
have expressed support for ‘risk-based monitoring’,
recognising that not all clinical trials require the same
approach to quality control and assurance. This is
reflected in the update of ICH GCP E6.19
One risk-based approach is ‘triggered’ or ‘targeted’
on-site monitoring. It was suggested as a possible
option for trials of investigational medicinal products
classed as low or medium risk by the Medicines and
Healthcare products Regulatory Agency, Medical
Research Council (MRC), and UK Department of
Health.16 An initial risk assessment determines the key
risks resulting from the intervention and the design of
the trial and strategies to minimise those risks are speci-
fied. If triggered monitoring is selected, over the course
of the trial sites are prioritised for visits based on cen-
tral monitoring ‘triggers’: predefined indicators such as
number of protocol deviations, case report form return
rates, uncommon patterns of serious adverse event
reporting or subjective assessments of site performance.
Such targeted monitoring is also mentioned as a possi-
ble approach in the update to ICH GCP E6.19
Although triggered monitoring approaches are not
uncommon3 and have clear potential benefits in terms
of resource-use, there is no empirical evidence to show
how well they work. TEMPER was designed to provide
such evidence.
Methods
Study design
TEMPER is a prospective, matched-pair study asses-
sing the value of triggered monitoring in distinguishing
sites with important protocol or GCP compliance
issues not identified centrally. Trials unit teams used
triggers to identify sites to visit (‘triggered visit’). Each
of these was matched with an ‘untriggered site’, and the
paired sites were visited and monitored according to
the trial’s monitoring plan. Site visit findings were cate-
gorised according to a standard classification based on
a high-level summary (Table 1). We compared the pro-
portion of triggered and untriggered visits with 1
Major/Critical finding not identified through central
monitoring or previous visits. The study design is sum-
marised in Figure 1. We developed a bespoke system,
the TEMPER Management System (TEMPER-MS) to
support implementation of the study.20
Ethics committee advice deemed no ethical review
was required because the additional site visits were
within the scope of each trial’s monitoring plan. To
ensure visits were arranged and conducted as per nor-
mal practice, site staff were not explicitly informed
about the TEMPER study or the reason for a monitor-
ing visit.
Trial selection
Included trials were conducted and monitored by the
MRC Clinical Trials Unit at University College
London; sponsored by the UK MRC; employing a trig-
gered monitoring strategy; investigational medicinal
products risk category B (‘somewhat higher risk than
standard medical care’) according to MRC/Department
of Health/Medicines and Healthcare products
Table 1. Classification of monitoring findings in TEMPER.
Grading Description
Critical Findings with potential to have serious impact on patient rights, safety or confidentiality
Findings that raise doubt about the accuracy or credibility of key trial data
Accumulation of Major findings
Major Deviations from the trial protocol which may result in some questionable data but without impact on trial results
Findings with potential, less serious impact on patient rights, safety or confidentiality
Accumulation of Other findings
Other Errors or deviations that have no important impact on data collection, patient safety or confidentiality
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Regulatory Agency risk classification.16 Trials also
needed to have started recruitment before 2012 and
plan follow-up to continue until after 2014.
Triggers
Triggers were based on those in use in the selected trials,
with some additional quantification where thresholds of
concern had not previously been defined. The triggers
were mainly quantitative although subjective ‘general
concerns’ could also be added to each site’s overall trig-
ger score in response to, for example, worrying contact
with a site or other more objective concerns not cap-
tured by the trial’s triggers. As risks and monitoring
needs changed over time, some new triggers were added
and/or thresholds modified (e.g. one trial demanded a
higher threshold for data return ahead of an interim
analysis). Table 2 summarises and exemplifies the trig-
ger types used by trial at the completion of TEMPER.
Site selection
We scheduled regular ‘trigger meetings’ (3–6 monthly
or more frequently if required) with trials unit teams to
review trigger data. Sites’ trigger scores were calculated
by the TEMPER-MS and reviewed by the trial teams
to decide which sites to visit. Chosen sites usually had
the highest total trigger scores, but general concerns
sometimes led to other sites being prioritised. All trig-
ger meeting discussions were documented.
To replicate real-life prioritisation by resource-
limited trial teams, we asked teams to distinguish
between sites that would definitely be visited in normal
practice (‘triggered-and-usually-visited’); and those,
usually with lower trigger scores, considered lower pri-
ority for a visit at that time (‘triggered-but-not-usually-
visited’); both are grouped as ‘triggered visits’ for the
primary analysis.
The TEMPER-MS matching algorithm proposed
‘untriggered’ sites to visit, minimising differences in (1)
number of patients and (2) time since first patient rando-
mised, while maximising differences in trigger score (see
Appendix in Supplementary Material and Diaz-Montana
et al.20). The closest match was accepted, unless there were
clearly documented reasons not to. For example, an
untriggered site that had been visited very recently outwith
TEMPER was replaced with the next closest match.
Site visits
To maximise similarity between triggered and untrig-
gered monitoring visits, they were all conducted accord-
ing to the trial’s monitoring plan with the same planned
checks at all visits in addition to follow-up of any spe-
cific concerns raised by the trials unit team. These
were broadly similar across the trials in the study:
Figure 1. TEMPER study design.
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monitoring usually included SDV on a sample of
patients and review of consent forms, pharmacy docu-
ments and facilities, and Investigator Site Files.
We aimed to conduct all visits within 3 months
after the trigger meeting, with paired visits as close
together as possible, and no more than 28 days apart.
The triggered visit was planned before its untriggered
match to help ensure that any changes to monitoring
visit approach implemented by the trial team at the
time of the triggered visit could be reflected in the
paired visit. All monitors performed the same roles at
site visits. Triggered visits were attended by
TEMPER-specific and trial-specific monitors, untrig-
gered visits only by TEMPER monitors. The same
GCP and monitoring training was undertaken both
by the trial team members attending visits and the
monitors; the latter also received trial-specific train-
ing. A TEMPER-specific monitoring visit report
ensured consistent reporting. Reports were written
and followed-up according to each trial’s monitoring
plan and trials unit procedures.
Data collection, finding classification and endpoint
definition
Findings were classified as ‘Critical’, ‘Major’ or ‘Other’
(see Table 1), with their final grade taking account of
any relevant response from the site to the monitoring
report. All Critical and Major findings were further
categorised as new or ‘already known prior to the
monitoring visit’ (e.g. through central monitoring or
self-reporting by the site). The latter were excluded
from the primary outcome, but included in the moni-
toring report to allow follow-up to resolution by the
trial team as required. The protocol provided detailed
guidance on appropriate gradings (see Online
Supplementary Material). This was updated to incor-
porate new findings as they arose. Selected findings
(related to consent and missed serious adverse events
in particular), if repeated to a predefined level, could
be ‘upgraded’ from ‘Other’ to ‘Major’ or from
‘Major’ to ‘Critical’. In these cases, one additional
finding of the higher grade was added to the total
findings for that visit.
Outcome measures
The primary outcome measure was the proportion of
sites with 1 Major or Critical finding not already iden-
tified through central monitoring or a previous visit
(‘new’ findings). Secondary outcomes were number of
Major and Critical findings, proportion of sites with
 1 Critical finding, number of Critical findings and
category of Major/Critical findings.
Table 2. Trigger types used during the course of TEMPER by trial.
Trigger type Description/example Total triggers per type per trial
Trial 1 Trial 2 Trial 3
General concern Subjective assessment of site performance and/
or objective concerns not covered by triggers
1 1 1
Overall CRF return rate Eg\ 80% of expected CRFs received + .20
CRFs outstanding
1 1 1
Return rate, specific CRF As above, for specific CRF 0 0 3
Return rate, Patient consent form As above for specific CRF 0 0 1
Data query rate (overall) Eg . 5% of data items missing or under query 1 1 1
Data query rate (specific question) As above, for specific data item 1 0 0
Data query resolution time Eg . 50% of missing or queried data items
outstanding for .3 months
1 1 1
SAE rate (high) Eg number SAEs/person years on
study . threshold (based on average for trial)
1 0 1
SAE rate (low) Eg number SAEs/person years on
study\ threshold (based on average for trial)
0 1 1
Protocol deviation (treatment) Eg treatment administered when clinical tests
out of range
1 9 0
Protocol deviation (eligibility) Eg date of investigation out of range 3 0 0
Protocol deviation (procedure) Eg failure to perform blood test when mandated 0 1 0
Protocol deviation (withdrawal rate) Eg . 20% of patients at site recorded as
completely withdrawn from trial
0 1 0
High recruitmenta .30 patients (Trial 1); .10% patients (trial 2 –
never met)
1 1 0
Total triggers assessed 11 17 10
CRF: case report form; SAE: serious adverse event.
aFor exploratory prognostic analyses, a high recruitment trigger was defined retrospectively for all trials as a site ranked in the top 10% of sites
ordered by recruitment.
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Sample size
Sample size calculations, based on review of previous
trials unit monitoring reports from trials using trig-
gered monitoring, assumed ;70% of triggered visits
would produce 1 new Major/Critical finding. To
detect an absolute reduction of 30% (from 70% to
40%) in untriggered sites, with 80% power and two-
sided significance level of 5%, required ;84 site visits
in 42 matched pairs. We sought balanced numbers of
visits across trials and required 50% of each trial’s
triggered visits to be ‘triggered and usually visited’. Ten
additional, unmatched visits were made to high recruit-
ing sites not otherwise selected for visits, to allow fur-
ther assessment of ‘high recruitment’ as a predictor of
findings in secondary analyses.
Analysis
The primary analysis was a two-group comparison of
the proportion of sites with 1 new Major/Critical
finding in the triggered versus untriggered groups.
Analyses of total numbers of Major and Critical find-
ings used one-sample t-tests of the within-pair differ-
ences. Prior to the first analysis, the TEMPER
Endpoint Review Committee recommended a sensitivity
analysis to exclude all findings related to re-consent, as
these typically communicated minor changes in side-
effect profile that could have been communicated with-
out requiring re-consent. A second, exploratory analysis,
excluded all consent-related findings because previous
research suggested that these could likely be identified
centrally.21,22
In secondary analyses, using all 94 visits, and with
additional information of potential prognostic value
obtained from questionnaires completed by the Trials
unit and site staff prior to the monitoring visits (see
Online Supplementary Material), the ability of individ-
ual triggers and site characteristics to predict on-site
findings was assessed by comparing the proportion of
visits with the outcome of interest (Eg  1 Major/
Critical finding) at sites where a trigger had/had not
fired. This utilised chi-square tests (with trend for
ordered categories) or Fisher’s exact test as appropriate
for univariate analyses and logistic regression for multi-
variate analyses.
Consistency
To reduce intra- and inter-observer bias, in addition to
Monitor training and the use of the categorisation sys-
tem, a Consistency Monitoring Group, comprising
trials unit staff from the participating trials’ teams, dis-
cussed suitable gradings for findings. The Endpoint
Review Committee comprised four experienced trialists
from the trials unit with no direct link to the trials, and
reviewed, for all visit reports and blind to whether the
visit was triggered or untriggered, all Major and
Critical findings and a selection of Other findings.
They also performed cross-visit reviews of similar sorts
of findings to ensure consistency of grading. The cate-
gorisation appendix and grading of relevant findings
from previous visits were updated if required following
Consistency Monitoring Group or Endpoint Review
Committee discussions.
Results
Three trials were included; all randomised, multicentre
(.100 sites) cancer treatment trials with a time-to-event
outcome measure (recurrence-free or overall survival),
planned accrual of .1000 patients and paper-based
data collection.
Site selection and matching
In total, 23 trigger meetings and 84 paired monitoring
visits took place between 2013 and 2016 (Figure 1).
Triggered and untriggered sites had mean trigger scores
of 4.0 (range of 2–6) and 0.8 (range of 0–3), respec-
tively. The matching algorithm gave mean within-pair
differences (triggered–untriggered) of -1.4 months (70.1
vs 71.5) in time since first randomisation and +8.5
(49.9 vs 41.4) in patients randomised.
Visit conduct
Three visits were .1 week outside the 3-month visit
window. Five untriggered visits were .28 days after
their triggered match, the longest gap being 4 months;
the continued suitability of the untriggered match as a
control was confirmed at the next trigger meeting. One
untriggered visit was before its triggered match because
of a short-notice postponement.
The median (interquartile range) number of trials
unit staff attending triggered and untriggered visits was
3 (2–3) and 2 (2–2), respectively (Wilcoxon p \ 0.01).
Visit conduct within pairs was similar in most respects:
full Investigator Site File checks were done at 25/42
triggered and 27/42 untriggered visits (p = 0.65), phar-
macy facility checks at 25 and 29, respectively
(p = 0.36), while the median (interquartile range)
number of patients undergoing SDV was 4 (3–5) and 4
(3–5), respectively (paired t-test p = 0.08). However,
more consent forms were checked at triggered (median
(interquartile range): 44 (27–77)) than untriggered visits
(35 (18–70)) (paired t-test p = 0.01).
Primary outcome: Major/Critical findings
Table 3 summarises all Major and Critical findings,
and Table 4 summarises the primary outcome; 88.1%
of triggered visits had 1 new Major/Critical finding,
compared to 81.0% of untriggered visits, an absolute
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difference of 7.1% (95% confidence interval (CI)
–8.3%, +22.5%; p = 0.365). When re-consent find-
ings were excluded, these figures reduced to 85.7% ver-
sus 59.5% (difference = 26.2% (95% CI 8.0%, 44.4%;
p = 0.007)); while excluding all consent and re-consent
findings reduced them further to 69.0% versus 45.2%
(difference = 23.8% (95% CI 3.3%, 44.4%;
p = 0.027)). Findings by trial are summarised in Table
S1 in the Online Supplementary Material.
Secondary outcomes
Critical findings (Online Supplementary Material Table
S2) were almost solely from consent form and source
data reviews. The majority (59%) were upgrades
because of a cumulative number of Major findings, and
the remainder were graded Critical in their own right.
The proportion of visits with Critical findings was
approximately halved in untriggered visits, but these
differences were of borderline statistical significance
(Table 4).
The median number of new Major and Critical find-
ings (Table 5) was three at triggered visits and one at
untriggered visits; the mean within-pair difference was
1.40 (95% CI –0.72, 3.53; p = 0.19) for all findings,
1.05 (95% CI 0.032, 2.06; p = 0.044) excluding re-
consent findings and 0.48 (95% CI –0.12, 1.08;
p = 0.12) excluding all consent findings (when the
Table 4. Primary and secondary binary outcomes.
Triggered Untriggered Between-group difference (95% CI) Chi-square test p value
N % N %
1 Major or Critical finding
All findings 37 88 34 81 7% (–8%, 23%) 0.365
Excluding re-consent findings 36 86 25 60 26% (8%, 44%) 0.007*
Excluding all consent findings 29 69 19 45 24% (3%, 44%) 0.027*
1 Critical finding
All Findings 15 36 8 19 17% (–2%, 35%) 0.087
Excluding re-consent findings 12 29 5 12 17% (0%, 34%) 0.057
Excluding all consent findings 10 24 5 12 12% (–4%, 28%) 0.150
CI: confidence interval.
*p values < 0.05.
Table 3. Summary of Major and Critical findings at TEMPER monitoring visits.
Type of finding by monitoring report section Number of findingsa No. (%) sites with  1
Major/Critical findingb
Major Critical
At presentationc Upgrade
onlyd
At presentation Upgrade
only
Investigator Site File – All 6 0 0 0 6 (7)
Informed consent – All 219 13 3 12 49 (58)
Re-consent (Eg failure to obtain
re-consent in a timely manner)
162 0 0 9
Original consent (Eg missing signatures,
missing or incompatible
signature dates, incorrect
versions used)
57 13 3 3
Pharmacy – All 6 0 2 0 5 (6)
CRF/SDV – All 67 3 9 8 43 (51)
Unreported SAE/notable event 25 0 0 4
Unreported endpoint 12 0 0 4
Source/priority data discrepancy 19 1 0 0
Other 11 2 9 0
Total Major and Critical findings 298 16 14 20 71 (85)
CRF: case report form; SDV: source data verification; SAE: serious adverse event.
aAll visits (n = 94).
bPaired visits only (n = 84).
c‘At presentation’ refers to findings attracting a Major or Critical grade on their own.
d‘Upgrade only’ refers to groups of findings from the same visit that, collectively, warranted a higher grade (e.g. a series of Major findings at the same
site could, in some circumstances, be upgraded to one additional Critical finding).
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median number of findings was 1 and 0, respectively).
The median number of new Critical findings was zero
at all visits.
Prognostic value of individual triggers
The ability of specific triggers to predict the presence of
Major and/or Critical findings at the site visit was
assessed across all outcomes (Online Supplementary
Material Tables S3 and S4). While the finding rates
tended to be higher when the trigger had been fired at
the time of site selection, only three triggers showed
even a modest association with outcome (p \ 0.05 for
at least one outcome, no adjustment for multiple test-
ing). These were ‘data query resolution time’, ‘protocol
deviation’ and ‘general concern’. Multivariate analyses
were carried out for each outcome measure, but
resulted in univariate models only, namely, the trigger
with the strongest association with that outcome mea-
sure in the univariate analysis.
High-recruiting sites were defined as the top 10% of
trial sites ordered by recruitment at the time of the site
visit. The prognostic value of high recruitment on out-
comes was investigated excluding all consent findings,
as the number of consent forms checked was directly
related to number of patients. We found no evidence of
higher finding rates at these sites.
Other site characteristics
Trials unit teams completed 90/94 pre-visit question-
naires. There was no clear evidence of a linear relation-
ship between the trial team ratings and the presence of
Major or Critical findings, including or excluding con-
sent findings (data not shown).
Pre-visit site questionnaires were provided by 76/94
sites. There was no evidence of a linear association
between the chance of 1 Major/Critical finding and
the number of active trials either per site or per staff
member. There was, however, evidence that the greater
the number of different trial roles undertaken by the
Research Nurse, the lower the probability of Major/
Critical findings. To a lesser extent, the reverse was true
for the principal investigator (see Online Supplementary
Material Table S5).
Discussion
We have shown that triggered monitoring, as used in
these trials, did not satisfactorily distinguish sites with
higher and lower levels of concerning on-site monitor-
ing findings. The pre-specified primary comparison
showed no significant difference between triggered and
untriggered visits in the proportion with 1 Major/
Critical finding not previously identified centrally.
However, over 70% of on-site findings related to issues
in recording informed consent, and 70% of these to re-
consent; the pre-specified sensitivity analysis excluding
re-consent findings demonstrated a clear difference in
event rate. There was some heterogeneity between trials
in the primary comparison, but much greater consis-
tency in the sensitivity and secondary analyses. In addi-
tion, there was some evidence that the trigger process
used could identify sites at increased risk of serious
concern: around twice as many triggered visits had 1
Critical finding, in the primary and sensitivity analyses.
Thus, we would suggest that triggered monitoring has
promise, but clearly needs refinement.
The categorisation framework we used is, we believe,
similar to those applied by regulators to the same find-
ings. However, these typically identify a finding of
importance in relation to an individual patient, when it
is only by accumulation that these are likely to have
serious impact on the trial as a whole. Risk-based mon-
itoring is not looking for perfection in trial data or con-
duct, but to detect errors that really matter. We found
no visit findings that raised serious issues that would
apply across sites, involved serious trial-wide safety
issues, or suggested any biases across trial arms which
would impact credibility of the trials’ results.
The prevalence of sites with Major and Critical find-
ings was higher than expected, echoing the experience
Table 5. Secondary continuous outcomes.
Triggered
Median (range)
Untriggered
Median (range)
Mean within-pair
difference (95% CI)
One-sample t-test
p value
Total Major and Critical findings
All findings 3 (0–24) 1 (0–33) 1.4 (–0.72, 3.53) 0.190
Excluding re-consent findings 1.5 (0–14) 0 (0–6) 1.05 (0.032, 2.06) 0.044*
Excluding all consent findings 1 (0–6) 0 (0–6) 0.48 (–0.12, 1.08) 0.120
Total Critical findings
All findings 0 (0–5) 0 (0–2) 0.29 (–0.054, 0.62) 0.096
Excluding re-consent findings 0 (0–5) 0 (0–1) 0.29 (–0.02, 0.59) 0.063
Excluding all consent findings 0 (0–2) 0 (0–1) 0.14 (–0.059, 0.34) 0.160
CI: confidence interval.
*p values < 0.05.
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of others.23 However, the great majority of our find-
ings, like others’,24 related to documenting the consent
process, for example, ensuring that correct versions are
used, and signatures and dates are present and consis-
tent with the timing of randomisation. The ‘quality by
design’ concept25 states the first course of action should
be preventive; informed consent form templates used
by academic clinical trials units should, therefore, be
reviewed to see if their design can be improved and
completion errors reduced. Timely central monitoring
of consent forms with adequate anonymisation22 may
mitigate the effects of many consent form completion
errors, particularly if trial treatment timelines mean
that full consent forms – or at least selected items – can
be reviewed before randomisation.
Re-consent was usually provoked by updates to
drug safety information, of which participants (at least
those still on treatment) should be aware. This can be a
lengthy process and therefore difficult to monitor cen-
trally. When re-consent is explicitly required, better
central monitoring methods are possible, perhaps using
site logs with lists of expected visit dates. However,
although regulatory guidance is clear that participants
must be informed about significant trial updates, the
method is not specified.19 Research Ethics Committees
and Institutional Review Boards may prefer formal,
documented informed re-consent, but this may not
always be necessary. Waiting until the participant’s
next trial visit may sometimes be inferior (certainly in
terms of speed) to sending an immediate letter to the
participants explaining the changes and asking them to
contact their site only if they have concerns.
Beyond consent processes, the majority of other
findings were identified from SDV activities. A growing
body of evidence suggests intensive SDV is often of lit-
tle benefit to randomised controlled trials, with any dis-
crepancies found having minimal impact on the
robustness of trial conclusions.11,12,26 SDV for a sample
of participants may be sufficient to detect systematic
problems,27,28 and focussing SDV only on key data
items may be appropriate and rational.
We carried out exploratory analyses of the prognos-
tic value of individual triggers to see if visits to sites at
which a specific trigger had fired were substantially
more likely to find Major or Critical findings than vis-
its to sites at which this trigger was not fired. The sam-
ple size was sufficient to detect an absolute difference
of approximately 30% in finding rates. Some triggers,
including high or low serious adverse event rates, were
rarely met so their prognostic value could not be
assessed. Three triggers were of potential, though still
at best modest value, given the multiple outcome mea-
sures assessed: the speed of data query resolution, pro-
tocol deviations and ‘general concern’. These triggers
were not wholly independent, and it was not possible
to combine them in a way that improved finding rate
discrimination more than our triggered/not triggered
visit categorisation. We note that high recruitment and
poor case report form return rates, although commonly
used as triggers3 were not of clear prognostic value.
Analysis of site staffing and workload suggested that
the fewer trial responsibilities held by the research
nurse, the higher the chance of a Major/Critical find-
ing, with a trend to the converse (mainly when findings
relating to consent are excluded), in relation to the
principal investigator. These findings suggest that,
while an insufficiently supported and possibly over-
stretched investigator may impact adversely on trial
conduct, an experienced, capable local Research Nurse,
able to take responsibility for many elements of trial
conduct, is key.
Ultimately, the sensitivity and specificity of triggered
monitoring depends on the selection of triggers. We
found Major and Critical findings at untriggered visits,
suggesting it remains necessary to visit these sites unless
central monitoring techniques can be improved or the
discriminatory value of triggers can increase. We used
the trials’ existing triggers – quantified more precisely
where needed to facilitate ranking of sites – without
any prior assessment of their potential value. The
search for more discriminatory triggers should encom-
pass work on Key Performance Indicators29 and
Central Statistical Monitoring.30 Subjective assessments
may be of value, but are perhaps more prone to incon-
sistency, particularly when staff turnover is high, and
therefore, harder to generalise. We might also optimise
current triggers, for example, with better (non-dichoto-
mous) treatment of continuous variables or greater
incorporation of temporal trends.
Planning, conducting and follow-up on monitoring
visits is time-consuming and therefore costly,2,8,9 so
maximising cost-benefit is key. We did not routinely
use triggers to guide the content of site visits which was
perhaps not optimal. Refined triggers could target spe-
cific activities, for example, data quality issues could
provoke SDV visits and general concerns could pro-
voke additional training. Prospective study of trigger-
defined visits is warranted.
Central monitoring enables review of information
across sites and time without the time constraints of a
site visit. Maximising these strengths would free more
time at visits for targeted SDV and activities best done
in-person, for example, process review, building rap-
port or training.
We acknowledge several limitations. TEMPER was
conducted in only three trials of similar type although
we see no reason to doubt its applicability to other
trials. The trials unit staff present at triggered and
untriggered visits were not blind to visit type.
TEMPER monitors were at all visits, but trial team
staff were only required to attend triggered visits.
However, the additional staff at triggered visits often
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included new trial staff attending for training purposes
and the planned activities were the same at all visits.
The only notable difference in completed activity
within pairs was the number of consent forms checked,
which was higher in the triggered visits compared to
the untriggered visits. While this could have increased
the chance of findings at triggered visits, this appears
not to have been the case, the difference in finding rates
being greater when consent findings were excluded.
Observation bias due to lack of blinding of monitoring
staff was mitigated by consistent training on the trials
and monitoring methods, the use of a common finding
grading system and independent review of all Major
and Critical findings which was blind to visit type.
The sample size was modest, but nonetheless ade-
quately powered to detect the minimal differences in
visit finding rates necessary to support the triggered
monitoring strategy employed in these trials. TEMPER
assessed the value of pre-existing triggers, rather than
first exploring the best triggers. Evidence to support
triggered monitoring comes largely from our sensitivity
and exploratory analyses, although these were pre-
planned, and recommended by an independent com-
mittee, which was blind to visit type.
Research into trial conduct rarely has the rigour we
demand of clinical trials. The motivation to study this
area comprises (1) the need to monitor trials effectively,
minimising risk to patients’ rights and safety and pro-
tecting data integrity and (2) the need to do so in a cost-
effective manner, noting that monitoring activities are a
major component of trial conduct costs at the coordinat-
ing centre. TEMPER is one of the few studies to address
monitoring strategies in a prospective manner,23,31,32 and
the first, we believe, to specifically evaluate triggered
monitoring. Its results should help challenge and guide
the future use of triggered monitoring.
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